Statements of Cash Flows (USD $)	9 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Cash Flows from Operating Activities:
Net income	$ 4,979,000	$ 5,138,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,489,000	1,629,000
Provision for bad debts	735,000	655,000
Stock issued for costs and expenses		384,000
Compensatory element of stock issuances	395,000	49,000
(Increase) decrease in operating assets, net:
Accounts, management fee and medical receivables	(3,552,000)	(1,430,000)
Notes receivable	82,000	57,000
Costs and estimated earnings in excess of billings on uncompleted contracts	640,000	(1,003,000)
Inventories	(89,000)	(936,000)
Prepaid expenses and other current assets	(615,000)	129,000
Other assets	(183,000)	106,000
Increase (decrease) in operating liabilities, net:
Accounts payable	515,000	(164,000)
Other current liabilities	1,214,000	550,000
Customer advances	882,000	(1,537,000)
Billings in excess of costs and estimated earnings on uncompleted contracts		800,000
Other liabilities	(39,000)	(18,000)
Due to related medical practices	2,000	(7,000)
Income tax payable	(100,000)	(75,000)
Net cash provided by operating activities	(6,355,000)	(4,327,000)
Cash Flows from Investing Activities:
Purchases of property and equipment	(568,000)	(606,000)
Cost of HDM acquisition	(40,000,000)
Cost of patents	(109,000)	(94,000)
Proceeds from non controlling interests	19,800,000	16,000
Sale to non controlling interest		10,000
Net cash used in investing activities	(20,877,000)	(674,000)
Cash Flows from Financing Activities:
Repayment of borrowings and capital lease obligations	(983,000)	(1,096,000)
Distributions to non controlling interests	(1,298,000)	(848,000)
Proceeds from long-term debt	14,000,000
Repayment of notes receivable from employee Stockholders	14,000	43,000
Net cash provided by (used in) financing activities	11,733,000	(1,901,000)
Net (Decrease) Increase in Cash and Cash Equivalents	(2,789,000)	1,752,000
Cash and Cash Equivalents - Beginning of Period	12,032,000	9,251,000
Cash and Cash Equivalents - End of Period	$ 9,243,000	$ 11,003,000